Keymed Biosciences

Keymed Biosciences is focused on developing innovative therapies for autoimmune diseases, tumors, and chronic diseases, with a pipeline that includes multiple Class I novel drug development programs

Biotech & Life Sciences

Sector

Seed

Stage

Biopharmaceutical development

Model

01Company Overview

Keymed Biosciences is focused on developing innovative therapies for autoimmune diseases, tumors, and chronic diseases, with a pipeline that includes multiple Class I novel drug development programs.

02Backed By2 investors

HCHankang Capital→3H3H Health Investment→

Is this your company? Claim your profile

Startup Intelligence by F4F4 Research Engine

Recent Activity

FROM 3H Health Investment

Participated in Timberlyne Therapeutics' $180M Series A financing to advance CM313, an anti-CD38 monoclonal antibody.

INVESTMENT·prnewswire.com+1

JAN 9, 2025

FROM 3H Health Investment

Portfolio company Keymed Biosciences received NMPA approval for stapokibart (康悦达®), the first domestically developed IL-4Rα antibody approved in China.